Mifamurtide for High-Grade, Resectable, Nonmetastatic Osteosarcoma Following Surgical Resection: A Cost-Effectiveness AnalysisJOHAL, Sukhvinder; RALSTON, Stephen; KNIGHT, Christopher et al.Value in health. 2013, Vol 16, Num 8, pp 1123-1132, issn 1098-3015, 10 p.Article

Osteosarcoma treatment ― Where do we stand? A state of the art reviewLUETKE, Anja; MEYERS, Paul A; LEWIS, Ian et al.Cancer treatment reviews. 2014, Vol 40, Num 4, pp 523-532, issn 0305-7372, 10 p.Article

mifamurtide (MEPACT°) Inefficace sur les ostéosarcomes et dangereux = Mifamurtide for osteosarcoma : a critical studyLa Revue Prescrire. 2010, Vol 30, Num 326, pp 889-892, issn 0247-7750, 4 p.Article

A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteersVENKATAKRISHNAN, Karthik; KRAMER, William G; SYNOLD, Timothy W et al.European journal of clinical pharmacology. 2012, Vol 68, Num 10, pp 1347-1355, issn 0031-6970, 9 p.Article

Developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care?DAVIES, J. E; NEIDLE, S; TAYLOR, D. G et al.British journal of cancer. 2012, Vol 106, Num 1, pp 14-17, issn 0007-0920, 4 p.Article